Company profile: Verogen
1.1 - Company Overview
Company description
- Provider of tailored next-generation sequencing solutions for forensic laboratories, including the MiSeq FGx Sequencing System (Forensic Genomics and Research Use Only modes); ForenSeq DNA Signature Prep, MainstAY, Kintelligence, and Imagen kits for human identification, kinship, and phenotypic/biogeographical ancestry; and Universal Analysis Software for data management, high-volume analysis, and reporting.
Products and services
- ForenSeq DNA Signature Prep Kit: High-throughput panel generating comprehensive DNA profiles for up to 96 samples, combining over 200 markers including autosomal, X-STRs, Y-STRs, and SNPs
- MiSeq FGx Sequencing System: Dual-mode instrument for human identification, featuring Forensic Genomics and Research Use Only modes to run next-generation sequencing tailored to forensic casework and research
- Universal Analysis Software: Modular platform with analysis modules for human identification workflows, enabling data management, high-volume analysis, and reporting for sequencing-based forensic genomics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Verogen
Verge Genomics
HQ: United States
Website
- Description: Provider of an AI-powered, all-in-human drug discovery platform (CONVERGE®) integrating proprietary human genomics and computational tools to predict new drugs; developer of VRG50635, a PIKfyve inhibitor for ALS; and collaborator with industry and academic partners, including Alexion/AstraZeneca Rare Disease, Eli Lilly, and SITraN, to co-develop clinical-stage and novel therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verge Genomics company profile →
Corlieve Therapeutics
HQ: France
Website
- Description: Provider of novel therapeutic options for patients with severe neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corlieve Therapeutics company profile →
Azitra
HQ: United States
Website
- Description: Provider of microbiome-based dermatology therapeutics and consumer products, offering bioengineered live biotherapeutic candidates ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and protein candidate ATR-01 for ichthyosis vulgaris; and a microbiome dermatology platform to develop products for skin disease treatment and skin appearance improvement; plus topical ointments and creams for dryness, redness, flakiness, and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azitra company profile →
Instant Labs
HQ: United States
Website
- Description: Provider of a fully-integrated, portable, and affordable real-time polymerase chain reaction (RT-PCR) platform for rapid, accurate pathogen detection, developing and marketing the Hunter Real-Time-PCR system. Focus areas include molecular diagnostic equipment, food safety testing equipment, and food verification testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instant Labs company profile →
ChromaCode
HQ: United States
Website
- Description: Provider of HDPCR-based molecular diagnostics and bioinformatics solutions for tumor profiling, minimal residual disease detection, and decentralized disease monitoring, paired with cloud software for automated interpretation, remote analysis, and scalable deployment; offerings include a multiplexed NSCLC panel delivering results in 24 hours with high concordance to NGS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ChromaCode company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Verogen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Verogen
2.2 - Growth funds investing in similar companies to Verogen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Verogen
4.2 - Public trading comparable groups for Verogen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →